Poster Proofs breast, receiving 97.2 mL of autologous adipose on average during each session. The most common indication for reconstruction in this study was found to be for aesthetic correction following mastectomy (90.6 % of patients). Fat grafting was most commonly used as an adjunctive therapy following initial implant (54.9% of patients) and flap (43.4% of patients) reconstruction. The time from first oncological surgery to fat grafting occurred after a mean of 27.51 months and median of 14 months. Following the completion of fat grafting, patients were followed by a plastic surgeon for an average of 1 month. Twenty-six complications were found to have occurred, resulting in a complication rate of 21.3% in this population of patients. The most commonly reported complications were liponecrosis (19.2% of complications) and infection (15.3% of complications). During oncologic follow up, six patients were reported to have experienced breast cancer recurrence following autologous fat grafting for reconstruction resulting in a recurrence rate of 4.8%. Additionally, of the 59 patients with reported radiologic follow up, seven patients exhibited radiological abnormalities in the postoperative period (11.9%).
CONCLUSIONS:
In this population of breast cancer patients who had mastectomy with reconstruction, fat transfer was not associated with a higher risk of cancer recurrence. Based on these preliminary findings, autologous fat grafting appears to be a relatively safe procedure for refinement of the reconstructed breast in postmastectomy patients. Our laboratory has been determining the ideal ASC subpopulation to be used in clinical trials. We have previously identified a subset of ASCs with a favorable gene expression profile that demonstrates improved wound healing in diabetic mice. This subset of cells can be isolated using a unique surface marker combination (CD26+/CD55+). In order to obtain sufficient numbers of these cells for therapeutic purposes, expansion of the cell line is necessary. Therefore, we tested whether expansion would result in changes to their transcriptional profiles.
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METHODS:
Adipose tissue was surgically extracted from three wild-type mice. The tissue was digested and single cells were subjected to fluorescence-activated cell sorting (FACS). Using this technique, cells were sorted for non-hematopoietic (CD45-), non-endothelial (CD31-) single cells with the progenitor cell marker (CD34+). This marker profile isolates all ASCs. Cells were also sorted for the ASC subpopulation of interest with the additional markers CD26 and CD55. Two sets of cultures were performed, one with parental ASCs and the other with CD26+/CD55+ ASCs. The cells were passaged every five days for a total of three passages (P 0 to P 3 ). Cells were trypsinized after each passage and analyzed by FACS to measure absolute cell numbers. Freshly isolated ASCs were subjected to single-cell transcriptional analysis and compared to the same group in culture after passages P 0 and P 1 .
RESULTS: Using the methods described above, three thousand parental ASCs and three thousand CD26+/ CD55+ ASCs were isolated. The number of cells from the parental group increased by two-fold in P 0 , nine-fold in P 1 , and over one hundred-fold in P 2 . The cells from the CD26+/CD55+ ASC group proliferated more than those in the parental group after each passage. Single-cell transcriptional analysis revealed a drastic drift in gene expression profiles between freshly isolated ASCs and those cells in culture. There were notable, statistically significant increases in genes VEGF, FGF2, FGF7, TGFB1, FGFR1, FGFR2, EGFR, CCND1, PCNA, ADAM10, and HB-EGF in the sorted ASCs in culture.
CONCLUSION:
Through single-cell transcriptional analysis, we have identified an ASC subpopulation that improves wound healing in diabetic mice. This study has offered insight into the changes that occur in ASCs with expansion. CD26+/CD55+ ASCs demonstrate an increased rate of proliferation in culture when compared to parental ASCs. Furthermore, during in vitro proliferation ASCs demonstrate an increase in expression of genes responsible for growth factors, growth factor receptors, proliferation and production of extracellular matrix. These findings continue to suggest that the CD26+/CD55+ ASC cell line is favorable for regenerative purposes and can be expanded in vitro for cell-based therapies.
